Sold as Duavee. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Bazedoxifene Acetate; Estrogens, Conjugated (sold as Duavee), first approved Oct 3, 2013, with 0 new uses approved and 0 published complete response letters.
| Endometriosis and Microvascular Dysfunction; Simvastatin and DuaveeEndometriosis · Penn State University | Phase 4 | Enrolling by invitation | Sep 28, 2021 |
| Phase IIB Trial of Bazedoxifene Plus Conjugated EstrogensRisk Reduction, Breast Cancer · University of Kansas Medical Center | Phase 2 | Active, not recruiting | Mar 29, 2021 |
| Affect of Duavive on Mood & Anxiety SymptomsMenopause, Depression, Anxiety · St. Joseph's Healthcare Hamilton | Phase 1 | Recruiting | Jul 20, 2020 |
| Advancing Postmenopausal Preventive TherapyAtherosclerosis, Cognitive Decline · University of Southern California | Phase 2 | Active, not recruiting | Sep 25, 2019 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 3, 2013 | DuaveeNDA 22247 · New molecular entity, new combination | Wyeth Pharms | 6 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA